Diabetes Care:多篇新发糖尿病患者长期随访研究提示,早期控糖真的很重要!

2021-10-12 MedSci原创 MedSci原创

不论年轻人还是老年人,良好的血糖控制必须尽早开始,并持续保持。

糖尿病控制与并发症试验(DCCT)和英国前瞻性糖尿病研究(UKPDS)使我们对糖尿病的自然史和管理有了基本的了解。其中包括强有力的证据:1)加强血糖管理可以限制糖尿病的一些并发症;2)HbA1c水平与并发症风险之间存在剂量反应关系;3)HbA1c<7.0%(<53mmol/mol)的治疗目标是现实的和适当的。

在研究计划结束后,对随机队列的持续观察进一步表明,在随机治疗阶段无法显示出血管事件和死亡率的改善,但在两组的血糖控制持平后的很长一段时间内,心血管事件和死亡率明显降低。在这两项研究中,由HbA1c评估的血糖控制在统计学上占了结果差异的大部分。

在近期《糖尿病护理》Diabetes Care的三篇文章中,DCCT和UKPDS研究者提供了更多关于在糖尿病自然史早期加强血糖控制的长期效果的信息。在两篇文章中的第一篇是基于对糖尿病干预和并发症流行病学(EDIC)研究中DCCT队列20多年的额外观察,报告了对微血管并发症数据的新分析。

这些数据补充了之前报道的证据,即尽管在停止随机比较治疗后不久两组的HbA1c值趋于一致,但在最初强化管理的队列中,微血管疾病的进展率持续较低。研究者们以前曾将这种现象称为 "代谢记忆"。在此,他们进一步报告了10年后结果差异的逐渐减弱。他们强调了对微血管并发症的增量效应和整个观察期的累积效应之间的区别,后者导致随机分组之间的持久差异。

在第二篇文章中,Lachin等人报告了在EDIC的20年观察期间,较早与较晚改善血糖控制对结果的影响的模型估计。他们比较了不同时间段的10年HbA1c 7.0.% (53 mmol/mol)与HbA1c 9.0% (75 mmol/mol)的效果。

在随机干预期间和停止干预后,高血糖的影响的替代模式。

这些模型估计,在20年的观察期间,与HbA1c 9.0%相比,7.0%的患者的心血管事件危险的减少超过50%;而HbA1c 开始为9.0%后将至7.0%减少仅为12%。同样,他们估计,较早地控制HbA1c 10年将使估计肾小球滤过率<60 mL/min/1.73 m2的新发病率减少>60%,而较晚地减少将导致危险性仅减少20%。

综上,不论年轻人还是老年人,良好的血糖控制必须尽早开始,并持续保持。

 

参考文献:

Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters. Diabetes Care 2021 Oct; 44(10): 2212-2215. https://doi.org/10.2337/dci21-0030

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1761701, encodeId=d1de1e617019d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 28 22:14:31 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639896, encodeId=9a52163989645, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 19 01:14:31 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902629, encodeId=d317190262994, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 05 08:14:31 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967235, encodeId=6404196e23527, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Mar 26 22:14:31 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716566, encodeId=ee521e16566f6, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Jul 02 21:14:31 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475141, encodeId=a2a014e51416b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 14 05:14:31 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059906, encodeId=bf681059906d6, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=528d5415815, createdName=ms8000001912619402, createdTime=Tue Oct 12 20:13:01 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059839, encodeId=7ba31059839cd, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67b5381061, createdName=ms7000000557124799, createdTime=Tue Oct 12 15:51:33 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059810, encodeId=e969105981057, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72615611943, createdName=ms8000001209014685, createdTime=Tue Oct 12 15:13:29 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1761701, encodeId=d1de1e617019d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 28 22:14:31 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639896, encodeId=9a52163989645, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 19 01:14:31 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902629, encodeId=d317190262994, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 05 08:14:31 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967235, encodeId=6404196e23527, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Mar 26 22:14:31 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716566, encodeId=ee521e16566f6, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Jul 02 21:14:31 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475141, encodeId=a2a014e51416b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 14 05:14:31 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059906, encodeId=bf681059906d6, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=528d5415815, createdName=ms8000001912619402, createdTime=Tue Oct 12 20:13:01 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059839, encodeId=7ba31059839cd, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67b5381061, createdName=ms7000000557124799, createdTime=Tue Oct 12 15:51:33 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059810, encodeId=e969105981057, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72615611943, createdName=ms8000001209014685, createdTime=Tue Oct 12 15:13:29 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1761701, encodeId=d1de1e617019d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 28 22:14:31 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639896, encodeId=9a52163989645, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 19 01:14:31 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902629, encodeId=d317190262994, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 05 08:14:31 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967235, encodeId=6404196e23527, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Mar 26 22:14:31 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716566, encodeId=ee521e16566f6, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Jul 02 21:14:31 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475141, encodeId=a2a014e51416b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 14 05:14:31 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059906, encodeId=bf681059906d6, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=528d5415815, createdName=ms8000001912619402, createdTime=Tue Oct 12 20:13:01 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059839, encodeId=7ba31059839cd, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67b5381061, createdName=ms7000000557124799, createdTime=Tue Oct 12 15:51:33 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059810, encodeId=e969105981057, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72615611943, createdName=ms8000001209014685, createdTime=Tue Oct 12 15:13:29 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1761701, encodeId=d1de1e617019d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 28 22:14:31 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639896, encodeId=9a52163989645, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 19 01:14:31 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902629, encodeId=d317190262994, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 05 08:14:31 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967235, encodeId=6404196e23527, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Mar 26 22:14:31 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716566, encodeId=ee521e16566f6, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Jul 02 21:14:31 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475141, encodeId=a2a014e51416b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 14 05:14:31 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059906, encodeId=bf681059906d6, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=528d5415815, createdName=ms8000001912619402, createdTime=Tue Oct 12 20:13:01 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059839, encodeId=7ba31059839cd, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67b5381061, createdName=ms7000000557124799, createdTime=Tue Oct 12 15:51:33 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059810, encodeId=e969105981057, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72615611943, createdName=ms8000001209014685, createdTime=Tue Oct 12 15:13:29 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1761701, encodeId=d1de1e617019d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 28 22:14:31 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639896, encodeId=9a52163989645, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 19 01:14:31 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902629, encodeId=d317190262994, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 05 08:14:31 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967235, encodeId=6404196e23527, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Mar 26 22:14:31 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716566, encodeId=ee521e16566f6, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Jul 02 21:14:31 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475141, encodeId=a2a014e51416b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 14 05:14:31 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059906, encodeId=bf681059906d6, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=528d5415815, createdName=ms8000001912619402, createdTime=Tue Oct 12 20:13:01 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059839, encodeId=7ba31059839cd, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67b5381061, createdName=ms7000000557124799, createdTime=Tue Oct 12 15:51:33 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059810, encodeId=e969105981057, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72615611943, createdName=ms8000001209014685, createdTime=Tue Oct 12 15:13:29 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2022-07-02 habb
  6. [GetPortalCommentsPageByObjectIdResponse(id=1761701, encodeId=d1de1e617019d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 28 22:14:31 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639896, encodeId=9a52163989645, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 19 01:14:31 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902629, encodeId=d317190262994, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 05 08:14:31 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967235, encodeId=6404196e23527, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Mar 26 22:14:31 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716566, encodeId=ee521e16566f6, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Jul 02 21:14:31 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475141, encodeId=a2a014e51416b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 14 05:14:31 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059906, encodeId=bf681059906d6, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=528d5415815, createdName=ms8000001912619402, createdTime=Tue Oct 12 20:13:01 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059839, encodeId=7ba31059839cd, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67b5381061, createdName=ms7000000557124799, createdTime=Tue Oct 12 15:51:33 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059810, encodeId=e969105981057, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72615611943, createdName=ms8000001209014685, createdTime=Tue Oct 12 15:13:29 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1761701, encodeId=d1de1e617019d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 28 22:14:31 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639896, encodeId=9a52163989645, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 19 01:14:31 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902629, encodeId=d317190262994, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 05 08:14:31 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967235, encodeId=6404196e23527, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Mar 26 22:14:31 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716566, encodeId=ee521e16566f6, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Jul 02 21:14:31 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475141, encodeId=a2a014e51416b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 14 05:14:31 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059906, encodeId=bf681059906d6, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=528d5415815, createdName=ms8000001912619402, createdTime=Tue Oct 12 20:13:01 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059839, encodeId=7ba31059839cd, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67b5381061, createdName=ms7000000557124799, createdTime=Tue Oct 12 15:51:33 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059810, encodeId=e969105981057, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72615611943, createdName=ms8000001209014685, createdTime=Tue Oct 12 15:13:29 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 ms8000001912619402

    学习了#学习#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1761701, encodeId=d1de1e617019d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 28 22:14:31 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639896, encodeId=9a52163989645, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 19 01:14:31 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902629, encodeId=d317190262994, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 05 08:14:31 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967235, encodeId=6404196e23527, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Mar 26 22:14:31 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716566, encodeId=ee521e16566f6, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Jul 02 21:14:31 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475141, encodeId=a2a014e51416b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 14 05:14:31 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059906, encodeId=bf681059906d6, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=528d5415815, createdName=ms8000001912619402, createdTime=Tue Oct 12 20:13:01 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059839, encodeId=7ba31059839cd, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67b5381061, createdName=ms7000000557124799, createdTime=Tue Oct 12 15:51:33 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059810, encodeId=e969105981057, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72615611943, createdName=ms8000001209014685, createdTime=Tue Oct 12 15:13:29 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 ms7000000557124799

    good

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1761701, encodeId=d1de1e617019d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 28 22:14:31 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639896, encodeId=9a52163989645, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Nov 19 01:14:31 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902629, encodeId=d317190262994, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 05 08:14:31 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967235, encodeId=6404196e23527, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Sat Mar 26 22:14:31 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716566, encodeId=ee521e16566f6, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Jul 02 21:14:31 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475141, encodeId=a2a014e51416b, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 14 05:14:31 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059906, encodeId=bf681059906d6, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=528d5415815, createdName=ms8000001912619402, createdTime=Tue Oct 12 20:13:01 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059839, encodeId=7ba31059839cd, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67b5381061, createdName=ms7000000557124799, createdTime=Tue Oct 12 15:51:33 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059810, encodeId=e969105981057, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72615611943, createdName=ms8000001209014685, createdTime=Tue Oct 12 15:13:29 CST 2021, time=2021-10-12, status=1, ipAttribution=)]
    2021-10-12 ms8000001209014685

    0

相关资讯

Diabetes Obes Metab:恩格列净与糖尿病患者尿酸代谢的关系

恩格列净降低了UA水平和痛风发作或减少了抗痛风药物处方的复合结局。这些具有临床意义的结果扩大了恩格列净作为T2D患者潜在抗痛风治疗的实用性。

Comput Methods Programs Biomed:十二指肠黏膜表面置换治疗2型糖尿病的临床研究

十二指肠粘膜表面置换(DMR)技术是一种相对较新的2型糖尿病治疗方法,已在人类中进行了试验。在这种创新策略中,将内镜导管置入十二指肠内,从而作为消融器械的引导。然后使用充满热流体的球囊进行环周消融,冷

Clin Gastroenterol Hepatol:脂肪胰会大大增加糖尿病患病风险!

脂肪胰是后续发生糖尿病独立相关,但与高血压或血脂异常无关

Clin Pharmacol Ther :2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关

目前,我国上市的降糖药物种类约有10中,其中包括新型降糖药物二肽基肽酶-4(DPP-4)抑制剂,胰高血糖素样肽-1受体激动剂(GLP-1 RA)和钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂等.

拓展阅读

改善糖尿病合并CKD患者结局的综合管理策略(IWGDF 2023)

改善糖尿病合并CKD患者结局的综合管理策略(IWGDF 2023)

Heliyon:糖尿病是发生慢性肾脏疾病的危险因素

糖尿病(DM)可能是CKD发展的独立危险因素。DM的早期筛查和监测对CKD的预防具有重要意义。

消渴名方——金芪降糖片:作用机制竟与这个信号通路有关!

金芪降糖片是我国第一个治疗2型糖尿病的口服中成药,对轻、中型2型糖尿病有较好的治疗效果。《中国2型糖尿病防治指南》报道,糖尿病前期患者服用金芪降糖片12个月,降低42%糖尿病的发病率。

JAMA子刊:患有糖尿病的青少年的心肺功能是否更差,体育锻炼是否更少?

该研究结果表明,与患有 T1D 的青少年相比,患有 T2D 的青少年CRF的缺陷更大,进一步呼吁采取新的干预措施,增加T2D青少年定期参加体育锻炼。

糖尿病诊断新指标!糖耐1小时血糖在此范围可确诊,且可更早发现患者

该立场声明提出75 g口服葡萄糖耐量试验(OGTT)后1小时血糖(1-h PG)检测可为一种更灵敏、更实用的方法,用于筛查高危人群的中度高血糖(IH)和2型糖尿病。

糖尿病加速脑力衰退?苏大附一薛群团队:认知能力下降速度加快近70%

在7年随访中,新发糖尿病与发病后约4年内的认知能力下降速度加快相关(与糖尿病前期相比,下降速度加快约68%),而糖尿病前期与非糖尿病人群相比则没有这样的变化趋势。